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Protocol
AbstrACt
Introduction Damage to peripheral nerves occurs in a 
variety of health conditions. Preserving nerve integrity, 
to prevent progressive nerve damage, remains a clinical 
challenge. Omega-3 polyunsaturated fatty acids (PUFAs) 
are implicated in the development and maintenance 
of healthy nerves and may be beneficial for promoting 
peripheral nerve health. The aim of this systematic 
review is to assess the effects of oral omega-3 PUFA 
supplementation on peripheral nerve integrity, including 
both subjective and objective measures of peripheral nerve 
structure and/or function.
Methods and analysis A systematic review of 
randomised controlled trials that have evaluated the 
effects of omega-3 PUFA supplementation on peripheral 
nerve assessments will be conducted. Comprehensive 
electronic database searches will be performed in Ovid 
MEDLINE, Embase, the Cochrane Central Register of 
Controlled Trials (CENTRAL), US National Institutes of 
Health Clinical Trials Registry and the WHO International 
Clinical Trials Registry Platform. The title, abstract and 
keywords of identified articles will be assessed for 
eligibility by two reviewers. Full-text articles will be 
obtained for all studies judged as eligible or potentially 
eligible; these studies will be independently assessed by 
two reviewers to determine eligibility. Disagreements will 
be resolved by consensus. Risk of bias assessment will be 
performed using the Cochrane Collaboration risk of bias 
tool to appraise the quality of included studies. If clinically 
meaningful, and there are a sufficient number of eligible 
studies, a meta-analysis will be conducted and a summary 
of findings table will be provided.
Ethics and dissemination This is a systematic review 
that will involve the analysis of previously published data, 
and therefore ethics approval is not required. A manuscript 
reporting the results of this systematic review will be 
published in a peer-reviewed journal and may also be 
presented at relevant scientific conferences.
PrOsPErO registration number CRD42018086297.
bACkgrOund 
description of the condition
The peripheral nervous system encompasses 
the nerves mediating sensory, motor and 
autonomic functions that are located outside 
of the brain and spinal cord. Alterations to 
the anatomical integrity of the peripheral 
nerves can adversely affect their function, 
presenting clinically as abnormal or loss of 
sensation, weakness and/or as changes to 
autonomic function.1 England describes 
peripheral neuropathy as ‘a general term 
that indicates any disorder of the peripheral 
nervous system’2; this is a broad definition 
that includes nerve damage due to a variety 
of aetiologies. The pathophysiological mech-
anisms underlying both the development and 
progression of peripheral neuropathy are 
complex and may depend on the cause. Some 
of these mechanisms include altered metab-
olism and intracellular signalling,3 vascular 
strengths and limitations of this study
 ► This will be the first systematic review to consider 
the efficacy and safety of omega-3 polyunsaturat-
ed fatty acid (PUFA) supplementation on peripheral 
nerve structure and function.
 ► This systematic review will only consider data from 
randomised controlled trials, which provide the high-
est level of evidence for single intervention studies.
 ► This review will be conducted according to the 
Cochrane Handbook for Systematic Reviews of 
Interventions and in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta 
Analyses statement.
 ► As we will include studies that have evaluated the 
use of omega-3 PUFA supplementation for treating 
any form of peripheral nerve damage, there may 
be limited scope to perform a meta-analysis due to 
clinical heterogeneity.
 ► There are currently no gold standard outcome mea-
sures for assessing peripheral neuropathy, which 
may affect the capacity to quantitatively synthesise 
data from individual studies to derive clear esti-
mates of treatment effect(s).
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and inflammatory stress4 and reactive oxygen species 
formation.5 
The most common systemic cause of peripheral 
neuropathy, which is evident in over 50% of individuals 
affected by the condition, is diabetes mellitus; the risk 
of peripheral neuropathy increases with longer disease 
duration6 and may be correlated with the degree of 
glycaemic control, particularly in type 1 diabetes.7–10 
Other causes include hereditary neuropathies (eg, Char-
cot-Marie-Tooth syndrome), post-infectious and inflam-
matory neuropathies (eg, Guillain-Barré syndrome) and 
drug-induced neuropathies (eg, platinum analogues, 
thalidomide and alcohol).11 Up to one-third of cases do 
not have an identified aetiology and are thus defined as 
idiopathic peripheral neuropathies.12
Clinical evaluations of peripheral nerve integrity gener-
ally include a combination of symptoms, signs and elec-
trodiagnostic studies, which aim to evaluate the extent 
of nerve damage.2 Symptoms and signs of nerve damage 
are often assessed using validated neuropathy scales or 
composite scores (which combine symptomatology with 
clinical measures of nerve function). Nerve biopsies are 
invasive and, as a result, not easily repeatable and are 
therefore not frequently used as an outcome parameter 
in longitudinal studies but are instead reserved for diag-
nostic purposes.13
Electrodiagnostic testing examines the characteris-
tics of the conduction of an electrical signal that travels 
through a single nerve. These tests are useful in providing 
diagnostic information and for longitudinally monitoring 
disease progression.14 Nerve conduction studies (NCSs) 
are reproducible and correlate well with underlying struc-
tural abnormalities,15 but the precision of these tests is 
limited to detecting changes in large myelinated nerve 
fibres, as they are not sufficiently sensitive to detect small 
nerve fibre damage.16 17 Quantitative sensory tests, which 
quantify thermal and pain thresholds, can be used to 
evaluate small nerve fibre function.17 Skin biopsies offer 
an alternative method to accurately diagnose and classify 
the extent of small fibre neuropathy, even in the absence 
of large fibre nerve damage.17 18 Cutaneous silent period 
testing is a reproducible measurement of the nociceptive 
spinal reflex, where thinly myelinated A-delta fibres are 
the afferent arm. Quantitative sudomotor axonal reflex 
testing assesses the function of unmyelinated postgan-
glionic sudomotor C fibres.19 20 These are among several 
other methods to assess various small fibre types, and as 
each individual test may have a relatively low sensitivity, a 
combination of modalities is usually preferable to better 
assess small nerve fibre function.21
Recently, corneal confocal microscopy has been applied 
to visualise small nerve fibres in vivo.22 This technique has 
been shown to correlate well with intraepidermal nerve 
fibre biopsy results23 and is useful for detecting and docu-
menting various types of small fibre neuropathies.24–27 
Corneal confocal microscopy has also been suggested 
to be useful for monitoring disease progression, and as 
a marker for improvements in nerve function, in the 
investigation of therapeutic targets for diabetic periph-
eral neuropathy.28–30
Peripheral neuropathies are typically treated based on 
their subtype and/or underlying cause(s). Treatments 
primarily aim to manage the underlying condition to 
prevent progressive nerve damage and to treat any asso-
ciated symptoms.2 16 31 The consequences associated with 
symptoms of neuropathic impairment do not only affect 
an individual’s quality of life, but also impart an economic 
burden in terms of healthcare costs and medical 
resources.32–34 This is especially true in chronic condi-
tions, such as diabetes, where lifetime care is required.3
description of the intervention
Omega-3 polyunsaturated fatty acids (PUFAs) are essen-
tial fatty acids (EFAs) with multiple double bonds, the 
first of which is located at the third carbon from the 
methyl end of the molecule. The short-chain omega-3 
PUFA, alpha-linolenic acid, found in plant sources, is a 
metabolic precursor to the long-chain omega-3 PUFAs 
docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA), which are present in high abundance in oily fish. 
As humans do not have the enzymes to synthesise these 
fatty acids de novo, omega-3 PUFAs must be obtained from 
the diet or through supplementation.35 The other major 
class of EFAs are the omega-6 fatty acids, which derive 
from the diet in the form of linolenic acid and are elon-
gated in vivo to gamma-linoleic acid and arachidonic acid 
(AA). Most eicosanoids derived from the omega-6-depen-
dent AA pathway are proinflammatory; in contrast, long-
chain omega-3 fatty acids bias prostaglandin metabolism 
towards the production of anti-inflammatory eicosanoids.
As omega-3 PUFAs competitively inhibit the metabolic 
conversion of omega-6 PUFAs,36 the balance of omega-3 
to omega-6 fatty acid consumption can affect systemic 
inflammatory processes and immune activity. The ratio of 
consumed omega-6 to omega-3 in typical Western diets is 
approximately 15 to 1, whereas a ratio of 4 to 1 is consid-
ered optimal.37 Increased consumption of omega-3 PUFAs 
is considered to provide a range of potential general 
health benefits, including a reduced risk of cardiovas-
cular disease38 39 and lowered systemic triglycerides.40 
DHA, as an integral component in cellular membrane 
structures of the brain and retina, has been implicated 
in perinatal visual and neural development.41–43 In ocular 
conditions, omega-3 fatty acids supplements can reduce 
the symptoms and clinical signs associated with ocular 
surface inflammation in dry eye disease.44 The American 
Heart Foundation recommends a daily intake, for adults, 
of 500 mg of long-chain omega-3 PUFAs45 and up to 4 g/
day in hypertriglyceridaemia.46
How the intervention might work
Once consumed, omega-3 PUFAs alter membrane 
protein activity and cellular signalling response to reduce 
immune activity and the concentration of systemic lipid 
inflammatory mediators.47 The incorporation of omega-3 
PUFAs into cellular membranes, and their subsequent 
 o
n
 24 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020804 on 25 March 2018. Downloaded from 
3Zhang AC, et al. BMJ Open 2018;8:e020804. doi:10.1136/bmjopen-2017-020804
Open Access
effect on membrane activity, has been shown to alter 
vascular function, improve sciatic nerve blood flow and 
enhance nerve conduction velocity (NCV) in a rat model 
of experimental diabetic neuropathy.48
Omega-3 PUFAs also affect intracellular signalling 
pathways and the expression of genes, some of which 
may be associated with the regulation of neuron growth 
and neuroprotection.49 In animal models of diabetes, 
omega-3 PUFA supplementation has been shown to 
attenuate adverse changes in nerve structure and func-
tion.50 51 Mice enriched with genes that increase endoge-
nous profiles of omega-3 PUFAs have been shown to have 
reduced neuronal cell death and increased recovery to 
mechanical stress and peripheral nerve injury.52 Omega-3 
PUFAs have also been demonstrated to promote neurite 
growth in rat sensory neurons.53
Derivatives of omega-3 PUFA metabolism, resolvins and 
protectins, which are oxygenated metabolites from EPA 
and DHA, respectively, may further promote neuronal 
function. Neuroprotectin D-1 has been shown to facilitate 
the regeneration of corneal nerves following refractive 
surgery and neurite growth from the trigeminal ganglion 
of mice54 and to prevent neuropathic pain after periph-
eral nerve injury.55
Why it is important to do this review
This will be the first systematic review to consider the 
potential effects of omega-3 PUFA supplementation on 
peripheral nerve integrity. Omega-3 PUFA supplemen-
tation has been shown to reduce neuronal damage and 
enhance recovery following nerve injury in experimental 
animal models of peripheral neuropathy. Confirmation 
of these effects in clinical populations would contribute 
significantly towards enhancing the clinical management 
of peripheral neuropathy. A therapeutic agent to prevent 
the pathogenesis of, or slow the progression of, peripheral 
nerve damage has the potential to greatly improve clinical 
outcomes. Furthermore, the potential for omega-3 PUFA 
supplements to alleviate neuropathy-associated symptoms 
would be predicted to reduce the impairment on an indi-
vidual’s quality of life and lessen the economic burden of 
peripheral neuropathy in the community.
ObjECtIvEs
The primary objective of this systematic review is to eval-
uate the efficacy and safety of oral omega-3 PUFA supple-
ments for improving peripheral nerve health. Efficacy 
outcomes will consider both subjective endpoints (ie, 
symptoms) and objective clinical measures, including 
changes to peripheral nerve structure and function.
MEtHOds And AnAlysIs
We will conduct the proposed systematic review and 
meta-analyses according to the recommendations stated 
in the Cochrane Handbook for Systematic Reviews of Interven-
tions56 and following the Preferred Reporting Items for 
Systematic Reviews and Meta Analyses (PRISMA) state-
ment.57 The protocol for this review has been registered 
in the PROSPERO International prospective register of 
systematic reviews (CRD42018086297).
Eligibility criteria
All studies published from the date of database inception 
until 21 November 2017 will be included. Studies will be 
selected according to the following eligibility criteria.
Types of studies
We will include randomised controlled trials (RCTs) where 
participants were allocated to consume oral omega-3 
PUFA supplements. We will exclude quasi-randomised 
trials. We will not exclude studies based on language, 
publication status, year or the number of participants. In 
cases where more than one publication reporting data 
from the same cohort of participants exist (ie, from the 
same trial), the study reporting on the largest number 
of participants will be included. Published conference 
abstracts will be eligible for inclusion.
types of participants
We will include studies involving adults (ie, aged 18 years 
or older), recruited from within any study setting, where 
the structure and/or function of peripheral nerves was 
assessed. To be eligible for inclusion in the review, studies 
need to include at least one subjective measure of periph-
eral neuropathy (eg, symptom score), one composite 
measure of peripheral neuropathy (ie, combining subjec-
tive and objective measures) or one objective measure of 
peripheral nerve structure (eg, nerve biopsy) or function 
(eg, NCSs).
types of interventions
We will consider interventions where participants were 
randomised to oral supplementation with short-chain 
and/or long-chain omega-3 PUFAs. We will accept studies 
that administered omega-3 supplements in any form or 
dosage. We will exclude studies where the intervention 
was administered in the form of dietary manipulation (ie, 
a food-based intervention), and where omega-3 PUFA 
supplements were administered in combination with 
another intervention (including other nutritional inter-
ventions), unless the intervention was administered in 
the same dose and frequency in the comparator group. 
We will consider studies where omega-3 PUFA supple-
ments were compared with placebo or no treatment.
types of outcome measures
There are no gold standard or universally accepted 
outcome measures for peripheral nerve assessment. In 
selecting the outcome measures for this review, we consid-
ered the recommendations provided by the European 
Neuromuscular Centre (ENMC) International workshop: 
Selection of Outcome Measures for Peripheral Neurop-
athy Clinical Trials (10–12 December 2014), taking into 
account both subjective and clinical measures.58
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We will assess all outcome measures at 6 months of 
follow-up, with an acceptable follow-up range of between 
3 and 9 months from baseline. If studies do not report the 
change from baseline, we will use data reported at the 
end of the follow-up period.
Primary outcomes
The primary outcome will be the change, from baseline, 
in peripheral neuropathy impairments, as quantified 
by validated, composite (ie, combining symptoms plus 
objective measures) neuropathy measures. We have not 
been prescriptive in our selection of particular scales as 
there are no universally agreed scoring systems; exam-
ples of validated, composite neuropathy assessment 
scales include the Michigan Diabetic Neuropathy Score,59 
Neuropathy Impairment Score (NIS)60 and Total Neurop-
athy Score.61 For the purpose of this review, we define a 
‘validated’ measure as a survey instrument that has been 
psychometrically tested.
secondary outcomes
We will consider the following secondary outcomes:
1. Symptoms: change, from baseline, in symptoms of 
peripheral neuropathy, measured by a validated, pa-
tient-assessed symptom score.
2. Pain: change, from baseline, in mean scores of pain, 
measured by a validated, patient-assessed pain scale. 
Examples of validated scales include the visual ana-
logue scale,62 Likert scales63 64 and the McGill Pain 
Questionnaire.65
3. Disability: change, from baseline, in the mean score 
of a patient-reported disability measure. Examples of 
validated disability measures include the Overall Neu-
ropathy Limitation Scale66 and the Overall Disability 
Sum Score.67
4. Anatomical markers:
a. change, from baseline, in central corneal nerve 
fibre length (CNFL), defined as the total length 
of nerves in a given area, measured in mm/mm2, 
using a laser-scanning in vivo confocal micro-
scope;
b. change, from baseline, in intraepidermal nerve fi-
bre density (IENFD).
5. NCSs: change, from baseline, in NCS parameters, as 
recommended by England (2005)68:
a. sensory nerve action potential (SNAP) amplitudes 
of the sural, median and ulnar nerves;
b. SNAP latencies of the sural, median and ulnar 
nerves;
c. sensory NCV of the sural, median and ulnar 
nerves;
d. distal compound motor action potential (CMAP) 
amplitude of the peroneal, tibial, median and ul-
nar nerves;
e. CMAP latency of the peroneal, tibial, median and 
ulnar nerves;
f. motor NCV of the peroneal, tibial, median and 
ulnar nerves;
g. minimum F-wave latency of the peroneal, tibial, 
median and ulnar nerves.
6. Sensory function in the cornea: change, from base-
line, in corneal sensation, as quantified using:
a. contact aesthesiometry: to quantify mechanical 
detection thresholds using the Cochet-Bonnet aes-
thesiometer (measured in millimetres);
b. non-contact aesthesiometry: to quantify corneal 
sensation quantified using an air-based aesthesi-
ometer (measured in millibars).
7. Sensory function in the skin: change, from baseline, 
in sensory function test scores:
a. mechanical detection thresholds, measured using 
pressure aesthesiometry (eg, von Frey hair aesthe-
siometer);
b. cold detection thresholds measured using quanti-
tative sensory testing (QST) methods;
c. warm detection thresholds measured using QST 
methods;
d. thermal pain thresholds, for cold and hot stimuli, 
measured using QST methods.
8. Adverse events: we will consider all adverse events and 
will analyse them in the following categories: (1) any 
adverse events, (2) adverse events leading to discon-
tinuation of the interventions and (3) serious adverse 
events, being those leading to hospitalisation or pro-
longed admission, a life-threatening event or death.
search methods for identification of studies
We will conduct comprehensive electronic database 
searches in: the Cochrane Central Register of Controlled 
Trials (CENTRAL) (Issue 10, October 2017), Ovid 
MEDLINE, Ovid MEDLINE Epub Ahead of Print, In-Pro-
cess & Other Non-Indexed Citations, Ovid MEDLINE 
Daily (January 1946–November 2017) and Embase 
(January 1947–November 2017). We will also search the 
US National Institutes of Health Clinical Trials Registry 
(www. clinicaltrials. gov) and the WHO International Clin-
ical Trials Registry Platform (www. who. int/ ictrp/ en/). 
We will not impose any restrictions on date or language in 
our search strategies. Search strategies for all electronic 
searches are included in online supplementary appen-
dices 1–5. We will additionally search the bibliographies 
of included RCTs to identify any other potentially rele-
vant studies.
data collection and analysis
After the search strategies are performed within each 
electronic database, the reference lists will be imported 
into EndNote. Duplicate entries will be identified and 
removed. The final reference library will be imported 
into Covidence,69 the standard production platform 
for Cochrane systematic reviews, for the study selection 
process.
selection of studies
The titles, keywords and abstracts of all unique articles, 
identified by the search strategies, will be independently 
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reviewed by two review authors to identify potentially 
eligible studies. The full-text papers of articles identified 
as relevant or potentially relevant, by at least one reviewer, 
will be retrieved for full-text screening. Full-text articles 
will be independently screened by two review authors and 
assessed for eligibility according to the prespecified inclu-
sion and exclusion criteria. Reasons for exclusion will be 
identified and recorded for ineligible studies that prog-
ress to the full-text screening stage. Any disagreements 
in eligibility assessment will be adjudicated between the 
two reviewers; if consensus cannot be achieved, a third 
independent author will be consulted to reach consensus. 
We will include a PRISMA flow diagram (summarising 
the article selection process) and a ‘Characteristics of 
excluded studies’ table (with reasons for study exclusion).
data extraction and management
Two review authors will independently extract outcome 
data and key study characteristics for all included studies. 
Any discrepancies will be resolved by discussion and 
consensus. We will contact the study authors of relevant 
trials, by email, if further information or clarification is 
required. If we fail to receive a response from the corre-
sponding author within 4 weeks, or if the authors are 
unable to provide us with the requested information, we 
will use the information that is available.
For each study, we will extract the following information:
1. article details: year of publication, journal of publica-
tion, language and publication status;
2. study details: dates study conducted, trial registration 
number, country, study setting, corresponding author 
details (name, institution, e-mail and address) and 
whether the study investigators were contacted for 
further information;
3. methods: exclusions after randomisation, losses to fol-
low-up, how missing data were handled and whether a 
sample size calculation was reported;
4. participants: number of participants in each interven-
tion group, participant baseline characteristics (ie, 
age, gender and/or sex (as specified by the study au-
thors), underlying conditions, peripheral neuropathy 
diagnostic criteria), participant inclusion criteria and 
exclusion criteria and comparison of groups at base-
line;
5. interventions: intervention(s) and comparator (type 
(long chain or short chain), dose (milligrams/day), 
duration of treatment), concomitant medications or 
treatments and compliance measures (ie, whether 
compliance was assessed, and the method used, eg, 
returned capsule counts and red blood cell fatty acid 
profiles);
6. outcomes: prespecified primary and secondary out-
come measures and time points of assessments;
7. other: sources of funding statement (ie, present or 
absent), actual source of funding (eg, industry fund-
ing), conflicts of interest statement (ie, present of ab-
sent) and nature of conflict of interest (eg, industry 
employee).
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of 
bias for each included study using the Cochrane Handbook 
for Systematic Reviews guidelines. Assessment of bias will be 
considered using the following domains:
1. selection bias (random sequence generation and allo-
cation concealment);
2. performance bias (blinding of participants and all 
study personnel);
3. detection bias (blinding of outcome assessors);
4. attrition bias (incomplete outcome data);
5. reporting bias (selective reporting of outcomes);
6. other sources of bias (funding source and conflicts of 
interest).
Each review author will judge the risk of bias in each 
domain as: (1) low risk, (2) unclear risk or (3) high risk. 
Disagreements in bias assessment will be resolved by 
consensus between the two review authors.
Measures of treatment effect
We will analyse data according to the methods described 
in Chapter 9 of the Cochrane Handbook for Systematic Reviews 
of Interventions.56
As all of the predefined outcomes are continuous 
measures, we will extract information on the change 
in mean from baseline, and standard deviation (SD) of 
change, for the intervention and comparison groups. 
If change from baseline is not reported, we will extract 
information on the mean and SD of the outcome, for 
the intervention and comparator groups, at the specified 
follow-up period. The effects of the interventions will be 
expressed as the mean difference, with 95% confidence 
intervals (CIs), between the intervention and comparator 
groups for significant outcomes (P<0.05); exact p values 
will be reported.
unit of analysis issues
The unit of analysis for this review will be the individual 
participant. In studies where outcomes were measured in 
ocular tissues, the unit of analysis will be the enrolled study 
eye of the participant. In studies where participants were 
randomly allocated to treatment, there will be no unit 
of analysis issues if only one eye per person is included 
in the trial, or if both eyes per person are included and 
the average value of both eyes are reported. In studies 
where participants were randomly allocated to treatment 
and both eyes were included, but reported separately, we 
will analyse this as clustered data (ie, adjusted for with-
in-person correlation). We may have to contact the trial 
investigators for further information to do this.
dealing with missing data
For any studies where missing outcome data (eg, omitted 
SD, standard errors) are identified, we will attempt to 
contact the study authors. If we fail to receive a response 
from the corresponding authors in 4 weeks, or if the 
authors are unable to provide us with the requested infor-
mation, we will use the information that is available. We 
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will use imputed data, if this has been derived by the trial 
investigators using an appropriate method, but will not 
impute missing data ourselves.
Assessment of heterogeneity
We will assess clinical and methodological heteroge-
neity in the included studies by examining differences in 
the intervention (eg, type, dose and form), participant 
characteristics at baseline (eg, age, gender/sex, cause of 
neuropathy, eligibility criteria) and risk of bias. We will 
quantify statistical heterogeneity using the I2 statistic, as 
outlined in Chapter 9 of the Cochrane Handbook for System-
atic Reviews of Interventions56; we will consider an I2 statistic 
of 60% or more as consistent with a moderate level of 
heterogeneity. In measuring heterogeneity, we will also 
consider the: (1) magnitude and direction of the effects 
of individual studies and (2) strength of evidence for 
heterogeneity (using a p<0.10 from the χ2 test as the crite-
rion for significant heterogeneity).
Assessment of reporting biases
If at least 10 studies are included in a meta-analysis, we 
will use a funnel plot to assess for any potential publica-
tion bias. We will interpret any asymmetries in the funnel 
plot in association with the trial characteristics, consid-
ering relevant factors such as sample size.
data synthesis
We will undertake meta-analyses, for the primary and/
or secondary outcomes, when this would be clinically 
meaningful (ie, for studies where the treatment, partici-
pants and the underlying clinical questions are similar). If 
fewer than three RCTs are to be included in a meta-anal-
ysis, we will use a fixed-effect model; otherwise, we will use 
a random-effects model.
If there is inconsistency between individual study results, 
such that the pooled results may not provide a fair repre-
sentation of the trial findings (eg, the effects are in oppo-
site directions or I2 >60% or the χ2 test p value is <0.10), 
we will not pool the study data but will instead describe 
the pattern of the individual study results. If there is statis-
tical heterogeneity but all of the effect estimates are in 
the same direction, such that a pooled estimate would 
seem to provide a good summary of the individual trial 
results, we may pool the data.
If a meta-analysis is not deemed appropriate, we will 
provide a descriptive or tabulated results summary.
subgroup analysis and investigation of heterogeneity
If sufficient data are available, we will perform subgroup 
analyses by prognostic factors (eg, type of disease 
(including subtype of diabetes), severity of peripheral 
neuropathy at baseline and age) and by potential inter-
vention effect modifiers (eg, dose, duration and type of 
omega-3 PUFA supplement), as these factors are poten-
tially important to any observed treatment effects.
sensitivity analysis
Provided there are sufficient data available, we will 
perform a sensitivity analysis for the primary outcome 
(ie, change in peripheral NIS), to assess the impact of 
excluding studies that: (1) were appraised as having a 
high risk of bias due to lack of allocation concealment 
or lack of blinding of participants and study personnel, 
(2) had more than 20% of participants that were lost to 
follow-up, (3) were unpublished and (4) were funded by 
industry.
summary of findings table
Provided that sufficient data are available, we will provide 
a ‘Summary of findings’ table for the primary outcome 
(change in peripheral neuropathy as measured using a 
validated composite neuropathy assessment) and the 
following secondary outcomes (as previously defined): 
(1) symptoms, (2) pain, (3) CNFL, (4) IENFD, (5) SNAP 
amplitudes of the sural nerve and (6) motor NCV of the 
peroneal nerve. We will follow the recommendations 
specified in chapter 11 of the Cochrane Handbook for System-
atic Reviews of Interventions.56 The strength and quality of 
the evidence for each outcome will be assessed using the 
Grading of Recommendations Assessment, Development 
and Evaluation approach.70
COnClusIOns
The term ‘peripheral neuropathy’ describes a heteroge-
neous group of disorders that cause damage to the periph-
eral nervous system. Currently, management approaches 
for peripheral neuropathy are aimed primarily at 
addressing the underlying cause and/or managing 
symptoms. For many causes of peripheral neuropathy, 
including diabetes, reversing or even limiting the progres-
sion of nerve damage remains a challenge with currently 
available therapeutics.
Omega-3 PUFAs are reported to be associated with a 
range of general health benefits that include reducing 
the risk of cardiovascular disease,38 39 lowering systemic 
triglycerides40 and improving clinical symptoms of dry eye 
disease.44 In animal models of experimental peripheral 
nerve injury, increasing endogenous levels of omega-3 
PUFAs have been shown to improve sciatic blood flow 
and accelerate the recovery of neuronal function.50 52 53
The aim of this systematic review is to assess the safety 
and efficacy of oral omega-3 PUFA supplementation for 
improving peripheral nerve health. If it is demonstrated 
that omega-3 supplements can improve measures of 
peripheral nerve function and/or quality of life, it is antic-
ipated that this therapy would make a valuable contribu-
tion to the current clinical management of peripheral 
neuropathy.
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